Further, GFAP, which shows higher plasma levels in AD patients as in other neurodegenerative diseases (see Other plasma biomarkers), has resulted decreased in salivary samples with a decreasing trend as AD proceeds [193]. This evidence concerns the gene GFAP and Alzheimer disease.